Journal article
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
- Abstract:
-
Background The recombinant vesicular stomatitis virus (rVSV) vaccine expressing the Zaire Ebola virus (ZEBOV) glycoprotein is efficacious in the weeks following single-dose injection, but duration of immunity is unknown. We aimed to assess antibody persistence at 1 and 2 years in volunteers who received single-dose rVSV-ZEBOV in three previous trials. Methods In this observational cohort study, we prospectively followed-up participants from the African and E... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 522.4KB, Terms of use)
-
- Publisher copy:
- 10.1016/S1473-3099(18)30165-8
Authors
- Publisher:
- Elsevier
- Journal:
- Lancet Infectious Diseases More from this journal
- Volume:
- 18
- Issue:
- 7
- Pages:
- 738-748
- Publication date:
- 2018-04-05
- Acceptance date:
- 2018-02-04
- DOI:
- EISSN:
-
1474-4457
- ISSN:
-
1473-3099
- Pubs id:
-
pubs:891270
- UUID:
-
uuid:9617ec77-41bd-40aa-9288-d3eeb9223b61
- Local pid:
-
pubs:891270
- Source identifiers:
-
891270
- Deposit date:
-
2018-07-27
- ARK identifier:
Terms of use
- Copyright holder:
- Huttner et al
- Copyright date:
- 2018
- Notes:
-
© 2018 The Authors. Published by Elsevier Ltd. This is the accepted manuscript version of the article. The final version is available online from Elsevier at:
https://doi.org/10.1016/S1473-3099(18)30165-8
If you are the owner of this record, you can report an update to it here: Report update to this record